This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy
by Zacks Equity Research
TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of -33.33% and 3.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 87.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Chinook Therapeutics (KDNY) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Chinook (KDNY) delivered earnings and revenue surprises of 1.61% and 83.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -34.86% and 1.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -29.17% and 47.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50% and 37.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics (NKTR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 2.47% and 0.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Radius Health (RDUS) delivered earnings and revenue surprises of 5.71% and 3.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 0.00% and 1.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will TherapeuticsMD (TXMD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -10.00% and -1.76%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD (TXMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50.00% and 6.12%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
TherapeuticsMD (TXMD) closed the most recent trading day at $1.63, moving +1.24% from the previous trading session.
TherapeuticsMD (TXMD) Surges: Stock Moves 6.8% Higher
by Zacks Equity Research
TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
TherapeuticsMD (TXMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 28.57% and 9.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate TherapeuticsMD (TXMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: TherapeuticsMD (TXMD) Q3 Earnings Expected to Decline
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
TherapeuticsMD (TXMD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -13.33% and -10.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?